DSpace Repository

Role of Botulinum Toxin a Injections as a Salvage Therapy for Refractory Overactive Bladder: Insights from Urodynamic Studies

Show simple item record

dc.contributor.author IVANOV, Mihaela
dc.contributor.author CEBAN, Emil
dc.date.accessioned 2023-11-15T07:11:25Z
dc.date.available 2023-11-15T07:11:25Z
dc.date.issued 2023
dc.identifier.citation IVANOV, Mihaela, CEBAN, Emil. Role of Botulinum Toxin a Injections as a Salvage Therapy for Refractory Overactive Bladder: Insights from Urodynamic Studies. In: 6th International Conference on Nanotechnologies and Biomedical Engineering: proc. of ICNBME-2023, 20–23, 2023, Chisinau, vol. 2: Biomedical Engineering and New Technologies for Diagnosis, Treatment, and Rehabilitation, 2023, p. 267-277. ISBN 978-3-031-42781-7. e-ISBN 978-3-031-42782-4. en_US
dc.identifier.isbn 978-3-031-42781-7
dc.identifier.isbn 978-3-031-42782-4
dc.identifier.uri https://doi.org/10.1007/978-3-031-42782-4_29
dc.identifier.uri http://repository.utm.md/handle/5014/24800
dc.description Acces full text - https://doi.org/10.1007/978-3-031-42782-4_29 en_US
dc.description.abstract The aim of study was to establish the role of botulinum toxin A (BTX-A) in the treatment of refractory idiopathic overactive bladder (OAB) patients and to find out if urodynamic values could predict the positive third line treatment response. Many clinicians use UDS to diagnose DO before detrusor injection treatment. According to NICE Guide it is mandatory to investigate “urodynamics” to confirm the diagnosis of DO before performing minimally invasive treatment such as BTX-A injections. Was obtained clinical data based on the necessity of performing urodynamic tests before BTX-A injection, at patients with idiopathic refractory OAB, ensuring effectiveness and long-lasting treatment, as well as providing predictive parameters for potential postoperative complications. A retrospective study was performed on 30 patients with OAB symptoms who followed first line therapy for 4 months, without any positive results. The study was performed during 2021–2022, at the Department of Urology, “Nicolae Testemitanu” USMF, Republic of Moldova. After 6 weeks of intravesical BTX-A injection, was demonstrated significant reductions in frequency, nocturia and quality of life compared to baseline. This study identified several urodynamic variables that are directly associated with clinical data, influencing the severity of symptoms in patients with refractory idiopathic OAB and the effectiveness of BTX-A injection as a treatment option, especially when it is a urodynamic confirmation of DO. The administration of 100 U of BTX-A through detrusor injection has been shown to be efficacious in the management of OAB with DO confirmed on urodynamic, in patients that are unresponsive to second line therapy. en_US
dc.language.iso en en_US
dc.publisher Springer Nature Switzerland en_US
dc.rights Attribution-NonCommercial-NoDerivs 3.0 United States *
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/3.0/us/ *
dc.subject Botulinum toxin en_US
dc.subject bladders en_US
dc.subject urodynamic studies en_US
dc.title Role of Botulinum Toxin a Injections as a Salvage Therapy for Refractory Overactive Bladder: Insights from Urodynamic Studies en_US
dc.type Article en_US


Files in this item

The following license files are associated with this item:

This item appears in the following Collection(s)

  • 2023
    6th International Conference on Nanotechnologies and Biomedical Engineering, September 20–23, 2023, Chisinau, Moldova

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 United States Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States

Search DSpace


Advanced Search

Browse

My Account